Badhri Srinivasan, head of global development operations at Novartis, outlines in an interview with Scrip the company’s efforts towards making clinical trials more efficient and decentralized, and how the Nerve Live data analytics platform is helping minimize non-performing sites.
Novartis AG is working on multiple fronts to improve the efficiency of clinical trials and reduce the burden of participation in such studies for patients. The Swiss multinational is using a range of partnerships across the health and technology ecosystems to drive some of its efforts in the area.
In an interview with Scrip, Badhri Srinivasan, head of global development operations at Novartis, outlined how alliances such as that...
A July white paper from Lifescience Dynamics explores the potential ways AI could see usage in pricing, reimbursement and market access for biopharma companies.
CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.
